Afinitor licensed for pancreatic tumours

Dosing is the same for all current indications: 10mg once daily
Dosing is the same for all current indications: 10mg once daily

Afinitor (everolimus) is now indicated for the treatment of advanced pancreatic neuroendocrine tumours in patients with unresectable or metastatic disease.

In the randomised, double-blind study, RADIANT-3 (n=410), median progression-free survival more than doubled with everolimus compared with placebo (11.0 vs 4.6 months).

Afinitor is also indicated for use in advanced renal cell carcinoma which has progressed during or after VEGF-targeted therapy. In addition, Novartis are launching everolimus as Votubia for the treatment of astrocytoma.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Two new steroid inhalers launched

Two new steroid inhalers launched

A new beclometasone metered-dose inhaler and a new...

Half of patients on statins do not reach cholesterol goals, study shows

Half of patients on statins do not reach cholesterol goals, study shows

Half of patients prescribed statins fail to reach their...

First oral hypoglycaemic licensed for add-on therapy in type I diabetes

First oral hypoglycaemic licensed for add-on therapy in type I diabetes

The SGLT2 inhibitor dapagliflozin (Forxiga) can now...

Quick-reference MIMS COPD prescribing resources updated

Quick-reference MIMS COPD prescribing resources updated

Concise MIMS resources on COPD management and antibiotic...